top border
top border
Featured Programs
Agent That Starves Tumor Cells May Improve Survival in Metastatic RCC
A novel glutaminase inhibitor CB-839, may provide a survival benefit in combination with cabozantinib (Cabometyx) by cutting off the energy supply to tumor cells in patients with metastatic renal cell carcinoma.
View Now
Treating Advanced Renal Cell Carcinoma
In this program moderated by Robert Figlin, MD, a panel of experts discusses modern day treatment of advanced kidney cancer. The discussants, Sandy Srinivas, MD; Nizar Tannir, MD, FACP; and Martin Voss, MD, focus on how to choose the right course of treatment for an individual patient.
View Now
Featured Webinar
HCC

An OncLive This week, we have collaborated with Weill Cornell Medicine to highlight important topics facing oncologists today. Join us Saturday, June 6, 2020 at 11 AM EST. View more


ASCO 2020 News

Gina ColumbusGina Columbus recaps on the latest news and speaks with leading oncologists from the 2020 ASCO Virtual Scientific Program.

Publication Bottom Border
Border Publication
x